+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
MALE
ID06654336

Randomized Trial Comparing Recurrence-Directed Therapy With or Without ELIGARD for Early Radio-Recurrent Oligo-Metastatic Hormone-Sensitive Prostate Cancer

Led by Ontario Clinical Oncology Group (OCOG) · Updated on 2026-10-13

162

Participants Needed

5

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether adding Androgen Deprivation Therapy ADT using the drug ELIGARD4 to Recurrence-Directed Therapy RDT improves progression-free survival in patients with early radio-recurrent oligo-metastatic castrate or hormone sensitive prostate cancer. This phase II randomized trial compares RDT plus ADT versus RDT alone in men with prostate adenocarcinoma who have developed a limited number of metastases after prior radiotherapy or surgery. The study aims to better understand treatment effects on disease progression and quality of life. Participants are randomly assigned to receive either RDT alone or RDT combined with ADT via ELIGARD4 injections every 3 months for 12 months. RDT involves radiotherapy or surgical removal targeting up to five metastatic sites. The trial monitors patients for up to 36 months from randomization, assessing disease status and treatment side effects. Follow-up visits occur every 3 months along with quality of life questionnaires. During the study, participants undergo regular clinical visits to evaluate progression-free survival, development of castrate-resistant prostate cancer, overall survival, and toxicities related to genitourinary and gastrointestinal systems. Quality of life is measured using validated questionnaires at months 3, 6, 15, and 36. The study also tracks time to additional therapies and adverse events, providing comprehensive data on treatment impact over three years.

CONDITIONS

Brief Title

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Research Team

L

Lisa Rudd-Scott, RN BScN

D

Daryl Solomon

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here